XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide
access via the World Wide Web to its presentation at the 2015 Credit
Suisse Healthcare Conference in Phoenix, Arizona. The live presentation
will occur at 9:30 a.m. Pacific Time (10:30 a.m. Mountain Time) on
Wednesday, November 11, 2015. A replay of the presentation will also be
available.
To access the live presentation via the Web, please go to www.XenoPort.com.
Please connect to the Website at least 15 minutes prior to the live
presentation to ensure adequate time for any software downloads that may
be necessary to listen to the Webcast.
A replay of the Webcast can be accessed for a minimum of one month and
will be available approximately 24 hours after the live presentation.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on commercializing
HORIZANT® (gabapentin enacarbil) Extended-Release Tablets in
the United States. XenoPort has entered into a clinical trial agreement
with the National Institute on Alcohol Abuse and Alcoholism (NIAAA)
under which the NIAAA has initiated a clinical trial evaluating
gabapentin enacarbil as a potential treatment for AUD. REGNITE®
(gabapentin enacarbil) Extended-Release Tablets is being marketed in
Japan by Astellas Pharma Inc. XenoPort has granted exclusive world-wide
rights for the development and commercialization of its clinical-stage
oral product candidate, arbaclofen placarbil, to Indivior PLC for all
indications. XenoPort’s other product candidates include XP23829, a
novel fumaric acid ester prodrug that is a potential treatment for
patients with moderate-to-severe chronic plaque-type psoriasis or
patients with relapsing forms of multiple sclerosis, and XP21279, a
prodrug of levodopa that is a potential treatment for patients with
idiopathic Parkinson's disease.
To learn more about XenoPort, please visit the Website at www.XenoPort.com.
HORIZANT, REGNITE and XENOPORT are registered trademarks of XenoPort,
Inc.
XNPT2G
View source version on businesswire.com: http://www.businesswire.com/news/home/20151029006472/en/
Copyright Business Wire 2015